000472: UTERINE SARCOMA

Introduction: Uterine sarcomas account for less than 1% of gynae- cologic malignancies and about 2-5% of all uterine cancer. Method: Retrospective study (1980-2000) of prospectively collected data from the Geneva Tumor Registry. Results: 56 patients with sarcomas, all localized in the uterus corpus...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of gynecological cancer 2005-09, Vol.15 (Suppl 2), p.182-182
Hauptverfasser: Neyroud, I., Usel, M., Vlastos, G., Dubuisson, J.B., Bouchardy, C., Vlastos, A.T.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 182
container_issue Suppl 2
container_start_page 182
container_title International journal of gynecological cancer
container_volume 15
creator Neyroud, I.
Usel, M.
Vlastos, G.
Dubuisson, J.B.
Bouchardy, C.
Vlastos, A.T.
description Introduction: Uterine sarcomas account for less than 1% of gynae- cologic malignancies and about 2-5% of all uterine cancer. Method: Retrospective study (1980-2000) of prospectively collected data from the Geneva Tumor Registry. Results: 56 patients with sarcomas, all localized in the uterus corpus were found. Median age is 60 years (30-85), 25% (14) are less than 50, 50% (28) are between 50 and 69 and 25% (14) are more than 70 year. The repartition of the different histological types is the following: Leiomyosarcomas 34% (19), Mullerian mixed tumor (heterologous type) 32% (18), Endometrial stromal sarcomas 20% (11), Carcinosarcomas (MMT of homologous type) 9% (5) and sarcomas 5% (3). FIGO staging was used to classified them. 5% (3) diagnosed at the stage 1b and 27% (15) at the stage 4b, in 38 cases the staging is missing. Local metastases were found in 53% of the cases (30), regional metastases in 16% (9) and distant metastases in 27% (15) at the time of the diagnosis (2 cases missing). Surgery was the treatment of choice for 89% (50) patients, associated with radiotherapy in 14% (7) and chemotherapy 20% (10). The median follow up is 6 years. 5 year overall survival was 37% (21), 80% died from uterine sarcoma and 20% died of other causes. Conclusion: Uterine sarcomas are rare cancers, often diagnosed at high stage with poor survival. Due to the difficulty of the diagnosis, a better knowledge of this pathology could improve an early detection and thereby a better treatment.
doi_str_mv 10.1136/ijgc-00009577-200509001-00468
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2552816764</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1048891X24204825</els_id><sourcerecordid>2552816764</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1464-255537d361c3f586b35a6918a1e6e384c52c4796640aa7d81123285a596ac7f23</originalsourceid><addsrcrecordid>eNqNkM1LAzEQxYMoWKtnrwXxGM3kO4KHUra1UC3UFryFmM3KFu3WpBX878266tm5zDC894b5IXQJ5AqAyet6_eIxyWWEUpgSIoghBPKKS32AeiCowMCZPswz4RprA0_H6CSldWuixPTQeZ64ojeD1bJYTB-KweNwMZrfD0_RUeVeUzj76X20GhfL0R2ezSfT0XCGPXDJMRVCMFUyCZ5VQstnJpw0oB0EGZjmXlDPlZGSE-dUqQEoo1o4YaTzqqKsjy663G1s3vch7ey62cdNPmlzNtUgleRZddupfGxSiqGy21i_ufhpgdiWhW1Z2F8W9o-F_WaR_ZPOH_IrH3WINvk6bHwo6xj8zpZN_c-kL3nZYwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2552816764</pqid></control><display><type>article</type><title>000472: UTERINE SARCOMA</title><source>Wiley Journals</source><creator>Neyroud, I. ; Usel, M. ; Vlastos, G. ; Dubuisson, J.B. ; Bouchardy, C. ; Vlastos, A.T.</creator><creatorcontrib>Neyroud, I. ; Usel, M. ; Vlastos, G. ; Dubuisson, J.B. ; Bouchardy, C. ; Vlastos, A.T.</creatorcontrib><description>Introduction: Uterine sarcomas account for less than 1% of gynae- cologic malignancies and about 2-5% of all uterine cancer. Method: Retrospective study (1980-2000) of prospectively collected data from the Geneva Tumor Registry. Results: 56 patients with sarcomas, all localized in the uterus corpus were found. Median age is 60 years (30-85), 25% (14) are less than 50, 50% (28) are between 50 and 69 and 25% (14) are more than 70 year. The repartition of the different histological types is the following: Leiomyosarcomas 34% (19), Mullerian mixed tumor (heterologous type) 32% (18), Endometrial stromal sarcomas 20% (11), Carcinosarcomas (MMT of homologous type) 9% (5) and sarcomas 5% (3). FIGO staging was used to classified them. 5% (3) diagnosed at the stage 1b and 27% (15) at the stage 4b, in 38 cases the staging is missing. Local metastases were found in 53% of the cases (30), regional metastases in 16% (9) and distant metastases in 27% (15) at the time of the diagnosis (2 cases missing). Surgery was the treatment of choice for 89% (50) patients, associated with radiotherapy in 14% (7) and chemotherapy 20% (10). The median follow up is 6 years. 5 year overall survival was 37% (21), 80% died from uterine sarcoma and 20% died of other causes. Conclusion: Uterine sarcomas are rare cancers, often diagnosed at high stage with poor survival. Due to the difficulty of the diagnosis, a better knowledge of this pathology could improve an early detection and thereby a better treatment.</description><identifier>ISSN: 1048-891X</identifier><identifier>EISSN: 1525-1438</identifier><identifier>DOI: 10.1136/ijgc-00009577-200509001-00468</identifier><language>eng</language><publisher>Oxford: Elsevier Inc</publisher><subject>Sarcoma</subject><ispartof>International journal of gynecological cancer, 2005-09, Vol.15 (Suppl 2), p.182-182</ispartof><rights>2005 IGCS</rights><rights>2005 2005 IGCS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Neyroud, I.</creatorcontrib><creatorcontrib>Usel, M.</creatorcontrib><creatorcontrib>Vlastos, G.</creatorcontrib><creatorcontrib>Dubuisson, J.B.</creatorcontrib><creatorcontrib>Bouchardy, C.</creatorcontrib><creatorcontrib>Vlastos, A.T.</creatorcontrib><title>000472: UTERINE SARCOMA</title><title>International journal of gynecological cancer</title><description>Introduction: Uterine sarcomas account for less than 1% of gynae- cologic malignancies and about 2-5% of all uterine cancer. Method: Retrospective study (1980-2000) of prospectively collected data from the Geneva Tumor Registry. Results: 56 patients with sarcomas, all localized in the uterus corpus were found. Median age is 60 years (30-85), 25% (14) are less than 50, 50% (28) are between 50 and 69 and 25% (14) are more than 70 year. The repartition of the different histological types is the following: Leiomyosarcomas 34% (19), Mullerian mixed tumor (heterologous type) 32% (18), Endometrial stromal sarcomas 20% (11), Carcinosarcomas (MMT of homologous type) 9% (5) and sarcomas 5% (3). FIGO staging was used to classified them. 5% (3) diagnosed at the stage 1b and 27% (15) at the stage 4b, in 38 cases the staging is missing. Local metastases were found in 53% of the cases (30), regional metastases in 16% (9) and distant metastases in 27% (15) at the time of the diagnosis (2 cases missing). Surgery was the treatment of choice for 89% (50) patients, associated with radiotherapy in 14% (7) and chemotherapy 20% (10). The median follow up is 6 years. 5 year overall survival was 37% (21), 80% died from uterine sarcoma and 20% died of other causes. Conclusion: Uterine sarcomas are rare cancers, often diagnosed at high stage with poor survival. Due to the difficulty of the diagnosis, a better knowledge of this pathology could improve an early detection and thereby a better treatment.</description><subject>Sarcoma</subject><issn>1048-891X</issn><issn>1525-1438</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkM1LAzEQxYMoWKtnrwXxGM3kO4KHUra1UC3UFryFmM3KFu3WpBX878266tm5zDC894b5IXQJ5AqAyet6_eIxyWWEUpgSIoghBPKKS32AeiCowMCZPswz4RprA0_H6CSldWuixPTQeZ64ojeD1bJYTB-KweNwMZrfD0_RUeVeUzj76X20GhfL0R2ezSfT0XCGPXDJMRVCMFUyCZ5VQstnJpw0oB0EGZjmXlDPlZGSE-dUqQEoo1o4YaTzqqKsjy663G1s3vch7ey62cdNPmlzNtUgleRZddupfGxSiqGy21i_ufhpgdiWhW1Z2F8W9o-F_WaR_ZPOH_IrH3WINvk6bHwo6xj8zpZN_c-kL3nZYwA</recordid><startdate>200509</startdate><enddate>200509</enddate><creator>Neyroud, I.</creator><creator>Usel, M.</creator><creator>Vlastos, G.</creator><creator>Dubuisson, J.B.</creator><creator>Bouchardy, C.</creator><creator>Vlastos, A.T.</creator><general>Elsevier Inc</general><general>BMJ Publishing Group LTD</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>200509</creationdate><title>000472: UTERINE SARCOMA</title><author>Neyroud, I. ; Usel, M. ; Vlastos, G. ; Dubuisson, J.B. ; Bouchardy, C. ; Vlastos, A.T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1464-255537d361c3f586b35a6918a1e6e384c52c4796640aa7d81123285a596ac7f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Sarcoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Neyroud, I.</creatorcontrib><creatorcontrib>Usel, M.</creatorcontrib><creatorcontrib>Vlastos, G.</creatorcontrib><creatorcontrib>Dubuisson, J.B.</creatorcontrib><creatorcontrib>Bouchardy, C.</creatorcontrib><creatorcontrib>Vlastos, A.T.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>International journal of gynecological cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Neyroud, I.</au><au>Usel, M.</au><au>Vlastos, G.</au><au>Dubuisson, J.B.</au><au>Bouchardy, C.</au><au>Vlastos, A.T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>000472: UTERINE SARCOMA</atitle><jtitle>International journal of gynecological cancer</jtitle><date>2005-09</date><risdate>2005</risdate><volume>15</volume><issue>Suppl 2</issue><spage>182</spage><epage>182</epage><pages>182-182</pages><issn>1048-891X</issn><eissn>1525-1438</eissn><abstract>Introduction: Uterine sarcomas account for less than 1% of gynae- cologic malignancies and about 2-5% of all uterine cancer. Method: Retrospective study (1980-2000) of prospectively collected data from the Geneva Tumor Registry. Results: 56 patients with sarcomas, all localized in the uterus corpus were found. Median age is 60 years (30-85), 25% (14) are less than 50, 50% (28) are between 50 and 69 and 25% (14) are more than 70 year. The repartition of the different histological types is the following: Leiomyosarcomas 34% (19), Mullerian mixed tumor (heterologous type) 32% (18), Endometrial stromal sarcomas 20% (11), Carcinosarcomas (MMT of homologous type) 9% (5) and sarcomas 5% (3). FIGO staging was used to classified them. 5% (3) diagnosed at the stage 1b and 27% (15) at the stage 4b, in 38 cases the staging is missing. Local metastases were found in 53% of the cases (30), regional metastases in 16% (9) and distant metastases in 27% (15) at the time of the diagnosis (2 cases missing). Surgery was the treatment of choice for 89% (50) patients, associated with radiotherapy in 14% (7) and chemotherapy 20% (10). The median follow up is 6 years. 5 year overall survival was 37% (21), 80% died from uterine sarcoma and 20% died of other causes. Conclusion: Uterine sarcomas are rare cancers, often diagnosed at high stage with poor survival. Due to the difficulty of the diagnosis, a better knowledge of this pathology could improve an early detection and thereby a better treatment.</abstract><cop>Oxford</cop><pub>Elsevier Inc</pub><doi>10.1136/ijgc-00009577-200509001-00468</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1048-891X
ispartof International journal of gynecological cancer, 2005-09, Vol.15 (Suppl 2), p.182-182
issn 1048-891X
1525-1438
language eng
recordid cdi_proquest_journals_2552816764
source Wiley Journals
subjects Sarcoma
title 000472: UTERINE SARCOMA
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T01%3A34%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=000472:%20UTERINE%20SARCOMA&rft.jtitle=International%20journal%20of%20gynecological%20cancer&rft.au=Neyroud,%20I.&rft.date=2005-09&rft.volume=15&rft.issue=Suppl%202&rft.spage=182&rft.epage=182&rft.pages=182-182&rft.issn=1048-891X&rft.eissn=1525-1438&rft_id=info:doi/10.1136/ijgc-00009577-200509001-00468&rft_dat=%3Cproquest_cross%3E2552816764%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2552816764&rft_id=info:pmid/&rft_els_id=S1048891X24204825&rfr_iscdi=true